Sichuan Biokin Pharmaceutical News

Sichuan Baili Tianheng Pharmaceutical Co., Ltd. voluntarily disclosed an announcement on the completion of the BL-B01D1 (EGFR×HER3-ADC) phase III clinical trial for EGFR-sensitive mutant locally advanced or metastatic non-small cell lung cancer that failed EGFR-TKI treatment

May 30 00:00

Sichuan Baili Tianheng Pharmaceutical Co., Ltd. voluntarily disclosed an announcement on the completion of the first clinical trial of BL-M07D1 (HER2-ADC) for locally advanced or metastatic HER2-positive breast cancer

May 27 00:00

Sichuan Baili Tianheng Pharmaceutical Co., Ltd. voluntarily disclosed an announcement on the completion of the first patient enrollment in the phase III clinical trial of BL-B01D1 (EGFR×HER3-ADC) for locally advanced, recurrent, or metastatic HR+HER2-breast cancer

May 22 00:00

Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders of Sichuan Baili Tianheng Pharmaceutical Co., Ltd.

May 18 00:00

Legal Opinion of Beijing Junhe (Chengdu) Law Firm on the 2023 Annual General Meeting of Shareholders of Sichuan Baili Tianheng Pharmaceutical Co., Ltd.

May 18 00:00

Explanation of relevant matters by Sichuan Baili Tianheng Pharmaceutical Co., Ltd.

May 14 00:00

Sichuan Baili Tianheng Pharmaceutical Co., Ltd. 2023 Annual General Meeting of Shareholders Meeting Materials

May 14 00:00

Sichuan Baili Tianheng Pharmaceutical Co., Ltd. voluntarily disclosed the announcement that the injectable BL-B16D1 (dual antibody ADC) program to treat advanced solid tumors obtained an approval letter for phase I clinical trials

May 10 00:00

Sichuan Baili Tianheng Pharmaceutical Co., Ltd. voluntarily disclosed the announcement that “BL-B01D1+PD-1 monoclonal antibody ± chemotherapy” has obtained approval notices for 7 phase II clinical trials to treat various advanced solid tumors

May 7 00:00

Sichuan Baili Tianheng Pharmaceutical Co., Ltd. 2023 Internal Control Evaluation Report

Apr 27 00:00

2023 Audit Committee Report of the Board of Directors of Sichuan Baili Tianheng Pharmaceutical Co., Ltd.

Apr 27 00:00

Special Report of the Board of Directors of Sichuan Baili Tianheng Pharmaceutical Co., Ltd. on the self-inspection of the independence of independent directors

Apr 27 00:00

Report of the Audit Committee of Sichuan Baili Tianheng Pharmaceutical Co., Ltd. on the performance of supervisory duties by accounting firms

Apr 27 00:00

Lixin Certified Public Accountants (Special General Partnership) Special Report on the Non-operating Capital Occupation and Other Related Capital Transactions of Sichuan Baili Tianheng Pharmaceutical Co., Ltd.

Apr 27 00:00

Sichuan Baili Tianheng Pharmaceutical Co., Ltd. 2024 “Improve Quality, Increase Efficiency and Value Return” Action Plan

Apr 27 00:00

Announcement of Sichuan Baili Tianheng Pharmaceutical Co., Ltd. on requesting the shareholders' meeting to authorize the board of directors to issue shares to specific targets through simple procedures

Apr 27 00:00

Notice of Sichuan Baili Tianheng Pharmaceutical Co., Ltd. on holding the 2023 Annual General Meeting of Shareholders

Apr 27 00:00

Sichuan Baili Tianheng Pharmaceutical Co., Ltd. voluntarily disclosed the notice of approval for the phase II clinical trial of “BL-B01D1+PD-1 monoclonal antibody ± chemotherapy” to treat locally advanced or metastatic non-small cell lung cancer

Apr 22 00:00

Sichuan Baili Tianheng Pharmaceutical Co., Ltd. voluntarily disclosed an announcement on the inclusion of injectable BL-B01D1 (EGFR×HER3-ADC) patients in the treatment of locally advanced or advanced nasopharyngeal cancer in the list of breakthrough treatm

Apr 18 00:00

Sichuan Baili Tianheng Pharmaceutical Co., Ltd. voluntarily disclosed an announcement on the completion of the first case of injectable BL-B01D1 (EGFR×HER3-ADC) for recurrent or metastatic esophageal squamous cell carcinoma phase III clinical trial

Apr 10 00:00